Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03475953
Title	A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE)
Acronym	REGOMUNE
Recruitment	Recruiting
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	Institut Bergonie
Indications	stomach carcinoma hepatobiliary system cancer hepatocellular carcinoma esophageal carcinoma differentiated high-grade thyroid carcinoma lung non-squamous non-small cell carcinoma gastrointestinal stromal tumor lung non-small cell carcinoma Advanced Solid Tumor neuroendocrine tumor colorectal cancer
Therapies	Avelumab + Regorafenib
Age Groups:	senior \| adult
Covered Countries	FRA